No edit summary |
Wikialpha49 (talk | contribs) further fixed section per standard format and corrected details |
||
| Line 1: | Line 1: | ||
{{short description|Indian multinational pharmaceutical company}} | {{short description|Indian multinational pharmaceutical company}} | ||
{{Use dmy dates|date=November 2018}} | {{Use dmy dates|date=November 2018}} | ||
{{Use Indian English|date=November 2018}} | {{Use Indian English|date=November 2018}} | ||
{{Infobox company | {{Infobox company | ||
| name | | name = Torrent Pharmaceuticals Limited | ||
| type | | former_name = Trinity Laboratories (<small>1959–1971</small>) | ||
| traded_as | | type = [[Public company|Public]] | ||
| traded_as = {{plainlist| | |||
*{{BSE|500420}} | *{{BSE|500420}} | ||
*{{NSE|TORNTPHARM}}}} | *{{NSE|TORNTPHARM}}}} | ||
| ISIN | | ISIN = {{ISIN|sl=n|pl=y|INE685A01028}} | ||
| logo | | logo = TorrentPharmalogonew.svg | ||
| foundation | | foundation = {{start date and age|1959}} | ||
| location | | location = [[Ahmedabad]], [[Gujarat]], India | ||
| | | founder = [[U. N. Mehta]] | ||
| key_people | | key_people = Sudhir Mehta<br>{{small|(Chairman Emeritus)}}<br>[[Samir Mehta]]<br>{{small|(Chairman)}}<br>Aman Mehta<br>{{small|(Managing director)}}<ref>{{cite web |title=Aman Mehta appointed Managing Director of Torrent Pharma |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aman-mehta-appointed-managing-director-of-torrent-pharma/articleshow/121296215.cms |website=The Economic Times |date=20 May 2025}}</ref> | ||
| area_served | | area_served = Worldwide | ||
| industry | | industry = [[Pharmaceutical industry|Pharmaceuticals]] | ||
| products | | products = {{hlist|[[Pharmaceutical]]s |[[Generic drug]]s |[[Over-the-counter drug]]s |[[Vaccine]]s |[[Medical diagnosis|Diagnostics]] |[[Contact lens]]es |[[Veterinary medicine|Animal health]] }} | ||
| revenue | | revenue = {{increase}} {{INRConvert|11516|c}} (2025) | ||
| operating_income = {{increase}} {{INRConvert| | | operating_income = {{increase}} {{INRConvert|3721|c}} (2025) | ||
| net_income | | net_income = {{increase}} {{INRConvert|1911|c}} (2025) | ||
| assets | | assets = {{decrease}} {{INRConvert|14990|c}} (2025) | ||
| equity | | equity = {{increase}} {{INRConvert|7591|c}} (2025) | ||
| num_employees | | num_employees = 12,881 (2020) | ||
| parent | | parent = [[Torrent Group]] | ||
| homepage | | homepage = [http://www.torrentpharma.com/ www.torrentpharma.com] | ||
| footnotes = Financials {{as of|2025|03|31|lc=y|df=yes}}.<ref name="fy24">{{cite web |title=Torrent Pharma announces Q4 FY25 results |url=https://www.torrentpharma.com/assets/Press_Release_8d03753387.pdf |website=Torrent Pharmaceuticals |access-date=28 May 2025}}</ref><ref>{{cite web |title=Results Q4 And Year Ended 31-03-2025 |url=https://www.torrentpharma.com/assets/Consolidated_Results_12a4aea34e.pdf |publisher=Torrent Pharmaceuticals Limited |access-date=28 May 2025}}</ref> | |||
}} | }} | ||
'''Torrent Pharmaceuticals Ltd''' is an Indian [[multinational | '''Torrent Pharmaceuticals Ltd''', [[d/b/a]] '''Torrent Pharma''', is an Indian [[multinational corporation|multinational]] [[pharmaceutical company]], part of the [[Torrent Group]] and headquartered in [[Ahmedabad]]. It was promoted by [[U. N. Mehta]], initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd. | ||
Torrent Pharmaceuticals operates in more than 40 countries with over | Torrent Pharmaceuticals operates in more than 40 countries with over 2,000 product registrations globally. Torrent Pharma is active in the therapeutic areas of cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective and pain management segments. It also has a presence in therapeutic segments of nephrology, oncology, gynecology, respiratory and pediatrics.<ref>{{cite news|url=https://business.medicaldialogues.in/torrent-pharma-q1-net-profit-up-33-percent-to-rs-216-crore/|title= Torrent Pharma Q1 net profit up 33 percent to Rs 216 crore | ||
|date=23 July 2019|work=Medical Dialogues}}</ref> | |date=23 July 2019|work=Medical Dialogues}}</ref> | ||
== | ==History== | ||
{{expand section|date=May 2024}} | |||
Torrent Pharmaceuticals was established in 1959 by [[U. N. Mehta]] as Trinity Laboratories. It was renamed Torrent Pharmaceuticals in 1971.<ref>{{cite news |title=Torrent Pharmaceuticals Ltd. |url=https://medicaldialogues.in/manufacturer/torrent-pharmaceuticals-ltd-2721747 |access-date=28 May 2024 |work=Medical Dialogues |date=7 September 2022 |language=en}}</ref> | |||
Torrent | In 1997, Torrent Pharma and [[Sanofi]] established a 50:50 joint venture called Sanofi Torrent for selling Torrent Pharma's products.<ref>{{cite news |title=Sanofi Torrent To Sell Torrent Pharma Products |url=https://www.business-standard.com/article/specials/sanofi-torrent-to-sell-torrent-pharma-products-197040701062_1.html |access-date=28 May 2024 |work=Business Standard |date=7 April 1997}}</ref> Torrent exited the joint venture by selling its stake to Sanofi in 2002.<ref>{{cite news |title=Torrent exits JV with Sanofi-Synthelabo: Reuters |url=https://www.rediff.com/money/2002/jan/30torren.htm |access-date=28 May 2024 |work=Rediff}}</ref> | ||
In 2005, Torrent Pharmaceuticals acquired Heumann Pharma Generics GmbH, a [[Pfizer]] company based in Germany.<ref>{{cite news |title=Torrent to buy Pfizer group's Heumann Pharma |url=https://economictimes.indiatimes.com/torrent-to-buy-pfizer-groups-heumann-pharma/articleshow/1154013.cms |access-date=28 May 2024 |work=The Economic Times |date=28 June 2005}}</ref> | |||
In 2013, Torrent Pharma acquired the India formulations business of [[Elder Pharmaceuticals]] for {{INRconvert|2004|c|mode=historical|year=2013}}.<ref>{{cite news |title=Torrent buys Elder Pharma business for Rs 2,004 crore |url=https://indianexpress.com/article/news-archive/web/torrent-buys-elder-pharma-business-for-rs-2-004-crore/ |access-date=28 May 2024 |work=The Indian Express |date=14 December 2013 |language=en}}</ref> | |||
In 2017, Torrent Pharma acquired the domestic business of [[Unichem Laboratories]] for {{INRconvert|3600|c|mode=historical|year=2017}}.<ref>{{cite news |last1=Rajagopal |first1=Divya |title=Torrent Pharma walks away with Unichem's domestic business for Rs 3,600 crore |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/torrent-pharma-to-buy-unichem-labs-india-business-for-558-million/articleshow/61489554.cms |access-date=28 May 2024 |work=The Economic Times |date=8 November 2017}}</ref> | |||
In 2022, the company acquired skincare manufacturer Curatio Healthcare for {{INRconvert|2000|c|mode=historical|year=2022}}.<ref>{{cite news |last1=Thacker |first1=Teena |title=Torrent Pharmaceuticals to acquire 100% of Curatio Healthcare for Rs 2,000 crores |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/torrent-pharmaceuticals-to-acquire-100-of-curatio-healthcare-for-rs-2000-crores/articleshow/94481136.cms |access-date=28 May 2024 |work=The Economic Times |date=27 September 2022}}</ref> | |||
==Recalls== | ==Recalls== | ||
In 2018, Torrent Pharmaceuticals recalled tablets containing [[valsartan]]<ref name=ucm617821>{{cite web |title=Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets |url=https://www.fda.gov/Safety/Recalls/ucm617821.htm |year=2018 |quote=<small>Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.</small>}}</ref><ref name=ucm613916>{{cite web |url=https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm |title=FDA updates on valsartan recalls |year=2018}}</ref> and [[losartan]]<ref name=ucm628966>{{cite web |title=Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP |url=https://www.fda.gov/Safety/Recalls/ucm628966.htm |year=2018 |quote=<small>Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.</small>}}</ref> due to the detection of [[N-nitrosodimethylamine|''N''-nitrosodimethylamine]] (NDMA) and [[N-Nitrosodiethylamine|''N''-nitrosodiethylamine]] (NDEA) respectively which are probable human carcinogens. | In 2018, Torrent Pharmaceuticals recalled tablets containing [[valsartan]]<ref name=ucm617821>{{cite web |title=Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets |website=[[Food and Drug Administration]] |url=https://www.fda.gov/Safety/Recalls/ucm617821.htm |archive-url=https://web.archive.org/web/20180827214854/https://www.fda.gov/Safety/Recalls/ucm617821.htm |url-status=dead |archive-date=27 August 2018 |year=2018 |quote=<small>Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.</small>}}</ref><ref name=ucm613916>{{cite web |url=https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm |archive-url=https://web.archive.org/web/20180724195435/https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm |url-status=dead |archive-date=24 July 2018 |title=FDA updates on valsartan recalls |website=[[Food and Drug Administration]] |year=2018}}</ref> and [[losartan]]<ref name=ucm628966>{{cite web |title=Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP |website=[[Food and Drug Administration]] |url=https://www.fda.gov/Safety/Recalls/ucm628966.htm |archive-url=https://web.archive.org/web/20181225045421/https://www.fda.gov/Safety/Recalls/ucm628966.htm |url-status=dead |archive-date=25 December 2018 |year=2018 |quote=<small>Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.</small>}}</ref> due to the detection of [[N-nitrosodimethylamine|''N''-nitrosodimethylamine]] (NDMA) and [[N-Nitrosodiethylamine|''N''-nitrosodiethylamine]] (NDEA) respectively which are probable human carcinogens. | ||
In September 2019, the FDA issued notice of a sixth [[product recall]] of losartan by Torrent Pharmaceuticals when certain batches of losartan contained the contaminant, N-methylnitrosobutyric acid (NMBA), above acceptable daily intake levels determined by the FDA.<ref name="fda9-23-19">{{cite web |title=Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP |url=https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0 |archive-url=https://web.archive.org/web/20190924062123/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-losartan-potassium-0 |url-status=dead |archive-date=24 September 2019 |publisher=US Food and Drug Administration |accessdate=23 September 2019 |date=23 September 2019}}</ref> | |||
== See also == | |||
* [[Pharmaceutical industry in India]] | |||
==References== | ==References== | ||
| Line 72: | Line 65: | ||
{{Nifty 200 companies}} | {{Nifty 200 companies}} | ||
[[Category:Pharmaceutical companies of Gujarat]] | |||
[[Category:Companies based in Ahmedabad]] | [[Category:Companies based in Ahmedabad]] | ||
[[Category:Pharmaceutical companies of India]] | [[Category:Pharmaceutical companies of India]] | ||
| Line 81: | Line 75: | ||
[[Category:Companies listed on the National Stock Exchange of India]] | [[Category:Companies listed on the National Stock Exchange of India]] | ||
[[Category:Companies listed on the Bombay Stock Exchange]] | [[Category:Companies listed on the Bombay Stock Exchange]] | ||
[[Category:Multinational companies headquartered in India]] | |||
{{med-company-stub}} | |||
Latest revision as of 05:13, 28 March 2026
 | |
Formerly | Trinity Laboratories (1959–1971) |
|---|---|
| Traded as | |
| ISIN | Template:ISIN |
| Industry | Pharmaceuticals |
| Founded | 1959 |
| Founder(s) | U. N. Mehta |
| Headquarters | Ahmedabad, Gujarat, India |
Area served | Worldwide |
Key people | Sudhir Mehta (Chairman Emeritus) Samir Mehta (Chairman) Aman Mehta (Managing director)[1] |
| Products | |
| Revenue |  ₹11,516 crore (US$1.6 billion) (2025) |
| ₹3,721 crore (US$520 million) (2025) | |
| ₹1,911 crore (US$270 million) (2025) | |
| Total assets |  ₹14,990 crore (US$2.1 billion) (2025) |
| Total equity | ₹7,591 crore (US$1.1 billion) (2025) |
Number of employees | 12,881 (2020) |
| Parent | Torrent Group |
| Website | www.torrentpharma.com |
| Footnotes / references Financials as of 31 March 2025[update].[2][3] | |
Torrent Pharmaceuticals Ltd, d/b/a Torrent Pharma, is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals operates in more than 40 countries with over 2,000 product registrations globally. Torrent Pharma is active in the therapeutic areas of cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective and pain management segments. It also has a presence in therapeutic segments of nephrology, oncology, gynecology, respiratory and pediatrics.[4]
History[edit | edit source]
![[icon]](/wiki/File:Wiki_letter_w_cropped.svg){kind=small} | This section needs expansion. You can help by adding to it. (May 2024) |
Torrent Pharmaceuticals was established in 1959 by U. N. Mehta as Trinity Laboratories. It was renamed Torrent Pharmaceuticals in 1971.[5]
In 1997, Torrent Pharma and Sanofi established a 50:50 joint venture called Sanofi Torrent for selling Torrent Pharma's products.[6] Torrent exited the joint venture by selling its stake to Sanofi in 2002.[7]
In 2005, Torrent Pharmaceuticals acquired Heumann Pharma Generics GmbH, a Pfizer company based in Germany.[8]
In 2013, Torrent Pharma acquired the India formulations business of Elder Pharmaceuticals for ₹2,004 crore (US$341.99 million).[9]
In 2017, Torrent Pharma acquired the domestic business of Unichem Laboratories for ₹3,600 crore (US$552.81 million).[10]
In 2022, the company acquired skincare manufacturer Curatio Healthcare for ₹2,000 crore (US$Expression error: Unexpected < operator.).[11]
Recalls[edit | edit source]
In 2018, Torrent Pharmaceuticals recalled tablets containing valsartan[12][13] and losartan[14] due to the detection of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) respectively which are probable human carcinogens.
In September 2019, the FDA issued notice of a sixth product recall of losartan by Torrent Pharmaceuticals when certain batches of losartan contained the contaminant, N-methylnitrosobutyric acid (NMBA), above acceptable daily intake levels determined by the FDA.[15]
See also[edit | edit source]
References[edit | edit source]
- ↑ "Aman Mehta appointed Managing Director of Torrent Pharma". The Economic Times. 20 May 2025.
- ↑ "Torrent Pharma announces Q4 FY25 results" (PDF). Torrent Pharmaceuticals. Retrieved 28 May 2025.
- ↑ "Results Q4 And Year Ended 31-03-2025" (PDF). Torrent Pharmaceuticals Limited. Retrieved 28 May 2025.
- ↑ "Torrent Pharma Q1 net profit up 33 percent to Rs 216 crore". Medical Dialogues. 23 July 2019.
- ↑ "Torrent Pharmaceuticals Ltd". Medical Dialogues. 7 September 2022. Retrieved 28 May 2024.
- ↑ "Sanofi Torrent To Sell Torrent Pharma Products". Business Standard. 7 April 1997. Retrieved 28 May 2024.
- ↑ "Torrent exits JV with Sanofi-Synthelabo: Reuters". Rediff. Retrieved 28 May 2024.
- ↑ "Torrent to buy Pfizer group's Heumann Pharma". The Economic Times. 28 June 2005. Retrieved 28 May 2024.
- ↑ "Torrent buys Elder Pharma business for Rs 2,004 crore". The Indian Express. 14 December 2013. Retrieved 28 May 2024.
- ↑ Rajagopal, Divya (8 November 2017). "Torrent Pharma walks away with Unichem's domestic business for Rs 3,600 crore". The Economic Times. Retrieved 28 May 2024.
- ↑ Thacker, Teena (27 September 2022). "Torrent Pharmaceuticals to acquire 100% of Curatio Healthcare for Rs 2,000 crores". The Economic Times. Retrieved 28 May 2024.
- ↑ "Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets". Food and Drug Administration. 2018. Archived from the original on 27 August 2018.
Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
- ↑ "FDA updates on valsartan recalls". Food and Drug Administration. 2018. Archived from the original on 24 July 2018.
- ↑ "Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP". Food and Drug Administration. 2018. Archived from the original on 25 December 2018.
Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
- ↑ "Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP". US Food and Drug Administration. 23 September 2019. Archived from the original on 24 September 2019. Retrieved 23 September 2019.
External links[edit | edit source]
{{URL|example.com|optional display text}}
| Companies | |
|---|---|
| People | |
